General Information of Drug Combination (ID: DC2TA3A)

Drug Combination Name
Hepzato TEM
Indication
Disease Entry Status REF
Astrocytoma Investigative [1]
Component Drugs Hepzato   DM2AZPP TEM   DMLNFWU
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: SNB-19
Zero Interaction Potency (ZIP) Score: 2.52
Bliss Independence Score: 6.59
Loewe Additivity Score: 3.24
LHighest Single Agent (HSA) Score: 2.24

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Astrocytoma DCXTN17 U251 Investigative [1]
Glioma DCN17TL SF-295 Investigative [1]
Invasive ductal carcinoma DCZ1CSG T-47D Investigative [4]
Invasive ductal carcinoma DCCBBXH HS 578T Investigative [4]
Adenocarcinoma DCF77QR SW-620 Investigative [5]
Amelanotic melanoma DC3DB6L MDA-MB-435 Investigative [5]
Amelanotic melanoma DCGVE6T M14 Investigative [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DrugCom(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030055)
4 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165
5 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976